<DOC>
	<DOCNO>NCT00439556</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose Velcade ( bortezomib ) give BEAM ( carmustine , etoposide , cytarabine melphalan ) rituximab patient lymphoma receive stem cell transplant .</brief_summary>
	<brief_title>Bortezomib Reduced Intensity Allogenic Stem Cell Transplantation Lymphoid Malignancies</brief_title>
	<detailed_description>Carmustine , etoposide , cytarabine , melphalan design kill lymphoma cell insert cell DNA . Rituximab monoclonal antibody target specific marker surface lymphoma cell cause die . Bortezomib work block proteasomes , cluster proteins necessary cancer cell growth . Cancer cell may sensitive drug like bortezomib tumor cell proteins normal cell . Bortezomib enters tumor cell affect way divide . When cancer cell divide , die . If find eligible take part study , receive carmustine needle vein 1 hour Day 1 . On Days 2-5 give cytarabine vein 1 hour etoposide vein 3 hour . This repeat every 12 hour Days 2-5 . On Day 6 give melphalan vein 30 minute . On Day 7 stem cell collect earlier donor give back ( `` transplant '' ) catheter 30-45 minute . You also receive rituximab vein , 5 7 hour transplant weekly , total 4 dos . In addition , receive match unrelated mismatch donor transplant , day 5-6 also give thymoglobulin vein 4-6 hour . Patients T-cell lymphoma receive Rituxan . Bortezomib give vein 1 minute 13 day , 6 day , 1 day transplant , 2 day transplant . G-CSF injected skin day blood count return normal level , start 7 day transplant . Sometimes infused donor cell cause inflammation skin , liver , gut , reaction call graft-versus-host disease ( GVHD ) occur . To prevent GVHD , tacrolimus give vein non-stop start 2 day transplant . It change oral tablet leave hospital . You take tacrolimus 6-8 month transplant . Methotrexate give purpose Days 1 , 3 , 6 transplant vein minute . Patients receive match unrelated mismatch donor also give methotrexate day 11 transplant . You require stay hospital 2 week transplant 2-3 week transplant . You must stay Houston area 100 day transplant . During first 100 day transplantation , blood ( 6 teaspoon ) draw routine test . Blood ( 20-30 teaspoon ) also draw daily hospital check effect transplant . You receive transfusion blood platelet need . You bone marrow biopsy/aspirate and/or chest x-ray doctor think necessary . Beginning 1 month transplantation , every 3 month 1 year , every 6 month 5 year , CT scan , positron emission tomography ( PET ) Gallium scan ( nuclear medicine test use special camera take picture special tissue ) , bone marrow biopsy/aspirate . These test do check status disease . You active study 5 year transplant . You take study disease get bad intolerable side effect occur . You talk study doctor want leave study early . If take study early , still may need return routine post-transplant follow-up visit , transplant doctor decides need . It may life-threatening leave study early conditioning regimen without follow stem cell transplant , blood cell count may dangerously low . This investigational study . Bortezomib rituximab FDA approve commercially available . Their use study , however , investigational since use transplantation . All chemotherapy drug FDA approve commercially available . Up 52 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>1 . Up 70 year age . 2 . Any histological subtype CD20+ lymphoid malignancy Tcell lymphoid malignancy . 3 . Patients CD20+ lymphoid malignancy relapse fail &gt; /= 1 prior regimen conventional treatment eligible nonmyeloablative transplant . Patients TCell lymphoid malignancy either relapse newly diagnose high risk feature ( high IPI &gt; /= 2 ) . 4 . Patients prior nonmyeloablative transplant eligible donor . 5 . A fullymatched oneantigen mismatch sibling unrelated donor . 6 . Left ventricular EF &gt; /= 40 % uncontrolled arrythmias symptomatic heart disease.. 7 . FEV1 , FVC DLCO &gt; /= 40 % . 8 . Serum creatinine &lt; 1.8 mg/dL . Serum bilirubin &lt; 3X upper limit normal , 9 . SGPT &lt; 3X upper limit normal . 10 . Voluntary sign , write IRBapproved informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . 11 . Men woman reproductive potential must agree follow accepted birth control method duration study . Female subject either postmenopausal surgically sterilize willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Male subject agrees use acceptable method contraception duration study . 1 . Past history anaphylaxis follow exposure rituximab VELCADE® , boron mannitol 2 . History grade 3 4 NCI toxicity prior VELCADE® therapy 3 . Patient active CNS disease . 4 . Pregnant ( Positive Beta HCG test woman child bear potential define postmenopausal 12 month previous surgical sterilization ) currently breast feed . Pregnancy test require postmenopausal surgically sterilize woman . 5 . Known infection HIV , HTLVI , Hepatitis B , Hepatitis C. 6 . Patients malignancy diagnose within 2 year prior Study Day 13 ( except skin squamous basal cell carcinoma ) . 7 . Active uncontrolled bacterial , viral fungal infection . 8 . Major surgical procedure significant traumatic injury within 4 week prior Day 13 . 9 . Serious , nonhealing wound , ulcer , bone fracture . 10 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 3 month prior Day 13 . 11 . History Stroke within 6 month . 12 . Myocardial infarction within past 6 month prior Study Day 1 , New York Heart Association ( NYHA ) Class III IV heart failure arrythmia , unstable angina , uncontrolled congestive heart failure arrythmias , electrocardiographic evidence acute ischemia active conduction system abnormalities.Prior study entry , ECG abnormality screen must document investigator medically relevant . 13 . Uncontrolled hypertension ( &gt; /=140/90 ) . 14 . Uncontrolled chronic diarrhea . 15 . A prior allogeneic transplant donor . 16 . Serious medical psychiatric illness likely interfere participation clinical study . 17 . Patient receive investigational drug within 3 week enrollment . 18 . Active peripheral neuropathy great equal grade 2 .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Velcade</keyword>
	<keyword>LDP-341</keyword>
	<keyword>MLN341</keyword>
	<keyword>PS-341</keyword>
	<keyword>Carmustine</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Etoposide</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Rituximab</keyword>
	<keyword>BEAM</keyword>
	<keyword>BCNU</keyword>
	<keyword>BiCNU®</keyword>
	<keyword>ARA-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt®</keyword>
	<keyword>Cytosine arabinosine hydrochloride</keyword>
	<keyword>VePesid®</keyword>
	<keyword>Rituxan</keyword>
</DOC>